Can a simple antiviral stop hepatitis b from waking up in lymphoma patients?
NCT ID NCT05453435
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether the antiviral drug entecavir can prevent hepatitis B from reactivating in people with a type of blood cancer (CD20-positive B-cell lymphoma) who have had hepatitis B in the past but cleared it. The 84 participants will take entecavir before starting their lymphoma therapy and continue for six months after. The goal is to see if this approach lowers the chance of the virus becoming active again.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Entecavir
- What this could lead to
- If successful, this could show that entecavir effectively prevents hepatitis B from reactivating in lymphoma patients during and after treatment, reducing liver complications.
- What could go wrong
- This is a small, single-arm phase 2 trial with no comparison group, so results may not be definitive. The drug may not prevent reactivation in all patients, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD20 POSITIVE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
Guangzhou, State..., 510060, China